Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 44,000 shares, a decline of 52.0% from the February 28th total of 91,700 shares. Based on an average daily trading volume, of 316,300 shares, the short-interest ratio is presently 0.1 days. Approximately 2.8% of the shares of the company are sold short.

Mustang Bio Stock Performance

NASDAQ MBIO traded down $0.09 on Friday, reaching $1.33. The stock had a trading volume of 73,124 shares, compared to its average volume of 244,964. The stock has a market cap of $1.27 million, a P/E ratio of -0.02 and a beta of 1.82. Mustang Bio has a 12-month low of $1.26 and a 12-month high of $65.00. The business’s 50-day moving average price is $2.65 and its 200 day moving average price is $8.03.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Geode Capital Management LLC raised its holdings in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 284,437 shares of the company’s stock after purchasing an additional 38,951 shares during the quarter. Geode Capital Management LLC owned about 29.63% of Mustang Bio worth $50,000 as of its most recent filing with the SEC. 9.95% of the stock is currently owned by institutional investors and hedge funds.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.